Lysostaphin (1200u/mg) |
Catalog No.GC19885
One-Click Copy Product Info
|
Lysostaphin is a zinc-containing metalloprotease with antibacterial activity.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 9011-93-2
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Lysostaphin is a zinc-containing metalloprotease with antibacterial activity. Lysostaphin specifically hydrolyzes the pentaglycine peptide bond bridges in the bacterial cell wall peptidoglycan to lyse staphylococcal cell walls, while also clearing persistent infections by disrupting biofilm structures. Lysostaphin can be used in research related to Staphylococcus aureus infections (including MRSA) and biofilm-associated infections (such as orthopedic implant infections and pneumonia)[1-4].
In vitro, KKU-213A and KKU-213B cholangiocarcinoma cell lines were treated with Lysostaphin (12.5μg/mL) for 72 hours. Lysostaphin significantly inhibited cell growth, induced apoptosis, and upregulated the expression of pro-apoptotic genes BAX, caspase-3, caspase-8, and caspase-9[5]. BALB/3T3 cells that had taken up Staphylococcus aureus A191, A151, and Cowan I were treated with Lysostaphin (1.25μg/ml) for 0 to 21 hours. Lysostaphin cleared extracellular bacteria, allowing intracellular Staphylococcus aureus to escape endosomes, proliferate, and induce apoptosis[6].
In vivo, 2-day-old newborn FVB mice subcutaneously infected with MRSA USA300 strain were intraperitoneally injected with Lysostaphin (10mg/kg or 15mg/kg; total of 4 doses) at 0.5, 6, 24, and 30 hours post-infection. Lysostaphin significantly improved the survival rate of infected mice, enhanced growth rate, and reduced colony counts in quantitative blood cultures[7]. Jugular vein catheterized mice infected with Staphylococcus aureus (including MRSA) were administered Lysostaphin (15mg/kg) combined with nafcillin (50mg/kg) through the catheter three times daily for 4 days. Lysostaphin combined with nafcillin eradicated established Staphylococcus aureus biofilms from implanted catheters and eliminated infections in the heart and liver[8].
References:
[1] Koening MG. Lysostaphin. J Infect Dis. 1969 Jan;119(1):101-2.
[2] Kumar JK. Lysostaphin: an antistaphylococcal agent. Appl Microbiol Biotechnol. 2008 Sep;80(4):555-61.
[3] Jayakumar J, Kumar VA, Biswas L, et al. Therapeutic applications of lysostaphin against Staphylococcus aureus. J Appl Microbiol. 2021 Sep;131(3):1072-1082.
[4] Zha J, Li J, Su Z, et al. Lysostaphin: Engineering and Potentiation toward Better Applications. J Agric Food Chem. 2022 Sep 21;70(37):11441-11457.
[5] Kerdkumthong K, Chanket W, Runsaeng P, et al. Two Recombinant Bacteriocins, Rhamnosin and Lysostaphin, Show Synergistic Anticancer Activity Against Gemcitabine-Resistant Cholangiocarcinoma Cell Lines. Probiotics Antimicrob Proteins. 2024 Jun;16(3):713-725.
[6] Murai M, Sakurada J, Seki K, et al. Apoptosis observed in BALB/3T3 cells having ingested Staphylococcus aureus. Microbiol Immunol. 1999;43(7):653-61.
[7] Placencia FX, Kong L, Weisman LE. Treatment of methicillin-resistant Staphylococcus aureus in neonatal mice: lysostaphin versus vancomycin. Pediatr Res. 2009 Apr;65(4):420-4.
[8] Kokai-Kun JF, Chanturiya T, Mond JJ. Lysostaphin eradicates established Staphylococcus aureus biofilms in jugular vein catheterized mice. J Antimicrob Chemother. 2009 Jul;64(1):94-100.
| Cell experiment [1]: | |
Cell lines | KKU-213A and KKU-213B cholangiocarcinoma cell lines, and MMNK-1 normal cholangiocyte cell line |
Preparation Method | Cells were plated at a density of 3×10³ cells/well in 96-well plates for viability assay or 2×10⁵ cells/well in 6-well plates for apoptosis assay and RNA extraction. On the next day, the cells were treated with Lysostaphin for 72 hours. |
Reaction Conditions | 12.5μg/mL; 72 hours |
Applications | Lysostaphin suppressed the growth of cholangiocarcinoma cells in a dose-dependent manner but had less effect on the normal cholangiocyte cell line. Lysostaphin induced cell apoptosis in both parental and gemcitabine-resistant cholangiocarcinoma cells. Treatment with Lysostaphin significantly upregulated the mRNA expression of the proapoptotic genes BAX, caspase-3, caspase-8, and caspase-9. |
| Animal experiment [2]: | |
Animal models | Jugular vein catheterized CF-1 mice |
Preparation Method | Jugular vein catheterized mice were challenged with Staphylococcus aureus (5×10⁵CFU/mouse) via tail vein injection and biofilm infections were allowed to establish for 5 days. Mice with established biofilms received various doses of recombinant Lysostaphin (ranging from 10 to 40mg/kg) |
Dosage form | 15mg/kg; through the catheter; administered three times per day for 4 days |
Applications | Lysostaphin in combination with nafcillin eradicated established Staphylococcus aureus biofilms from implanted catheters and sterilized heart and liver infections of S. aureus-infected mice. |
References: | |
| Cas No. | 9011-93-2 | SDF | |
| Formula | M.Wt | 28.2kDa | |
| Solubility | Soluble in 50mmol/L tris-Cl | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 35.5 μL | 177.3 μL | 354.6 μL |
| 5 mM | 7.1 μL | 35.5 μL | 70.9 μL |
| 10 mM | 3.5 μL | 17.7 μL | 35.5 μL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Potency: >1200U/mg Protein Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 25 reference(s) in Google Scholar.)